Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond

Abstract excerpt

Although 70% to 80% of epithelial ovarian cancers respond to chemotherapy, less than 30% of patients can be cured with cytoreductive surgery combined with the best currently available drugs. Over the last three decades, the median survival for patients with ovarian cancer has improved significantly, but the plateau of the survival curve has not changed appreciably. Empirical combinations of up to five...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to BRCA gene mutations in cancer
• Share to Ovarian cancer diagnosis and treatment
• Share to PARP inhibition in cancer therapy